Bank of America Comments on FDA Approval of Bruker Corporation's MALDI Biotyper CA System

In a report published Friday, Bank of America analyst Derik de Bruin reiterated a Buy rating and $25.00 price target on Bruker Corporation (NASDAQ: BRKR ). In the report, Bank of America noted, “On 11/26, BRKR announced that it received 510-k approval for its MALDI Biotyper CA System, a mass